What's Happening?
Simulations Plus, Inc., a leader in AI-accelerated drug development, has announced its financial results for the second quarter of fiscal 2026, ending February 28, 2026. The company reported an 8% increase in total revenue, reaching $24.3 million, with
software revenue contributing 60% and services revenue 40%. The gross profit rose to $16.1 million, with a gross margin of 66%. Net income was reported at $4.5 million, with diluted earnings per share of $0.22. Adjusted EBITDA was $8.7 million, representing 36% of total revenue. The company has adjusted its fiscal 2026 guidance for adjusted diluted EPS due to an increase in the expected effective tax rate.
Why It's Important?
The financial performance of Simulations Plus highlights the growing demand for AI-driven solutions in drug development. The company's ability to increase revenue and maintain strong profit margins indicates robust market conditions and favorable pricing agreements. This performance is significant for stakeholders in the biopharma industry, as it reflects the potential for continued innovation and growth in AI-accelerated drug development. The adjusted guidance for fiscal 2026 suggests a cautious approach to tax implications, which could impact future profitability.
What's Next?
Simulations Plus plans to host a conference call and webcast to discuss its financial results and future outlook. The company aims to continue leveraging AI and cloud-based solutions to drive growth and innovation in drug development. Stakeholders can expect further updates on fiscal guidance and strategic initiatives during the conference call.
